Nurexone Biologic Inc News - NRX

FeaturedSouthern Silver Files NI43-101 Technical Report for its Updated Preliminary Economic Assessment for the Cerro Las Minitas Project

NurExone establishing State-of-the-Art Research and Development Facility in Haifa, Israel

TORONTO and HAIFA, Israel, March 08, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (Germany:...

NurExone Presenting Novel Regulatory Pathways for Exosomes Therapies at Global Summit

TORONTO and HAIFA, Israel, March 01, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (Germany:...

NurExone’s Intellectual Property Portfolio Expands

TORONTO and HAIFA, Israel, Feb. 20, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (Germany:...

NurExone Launches Licensing Efforts for ExoTherapy Platform

TORONTO and HAIFA, Israel, Feb. 14, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (Germany:...

Nurexone Biologic Initiates European Orphan Drug Designation Process Following U.S. Grant

TORONTO and HAIFA, Israel, Feb. 02, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90...

NurExone and Inteligex Kick Off Chronic Spinal Cord Injury Research for Multi-Billion Dollar Healthcare Market

TORONTO and HAIFA, Israel, Jan. 17, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90...

NurExone Announces Closing of a Private Placement for Gross Proceeds of Approximately CAD$2 Million

TORONTO and HAIFA, Israel , Jan. 05, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90...

NurExone Biologic Extends Spinal Cord Injury Therapy Portfolio With New RNA Sequences Promoting Healing and Regeneration

TORONTO and HAIFA, Israel, Nov. 29, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90...

NurExone Reports Third Quarter 2023 Financial Results and Provides Corporate Update

TORONTO and HAIFA, Israel, Nov. 24, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90...

Take Part in the Next Generation of Spinal Cord Injury Treatments with These Companies

For anyone with a spinal cord injury (SCI), time is of the essence. The typical treatment scenario involves immobilization and surgery as quickly...

Orphan Drugs Worth $64 Billion by 2028 and This Micro Cap Could Have One by That Time

There are very good reasons that stocks generally gain in value after a company receives orphan drug designation (ODD). A

When Technicals and Fundamentals Converge, A Nice Uptrend Ensues

Some investors only pay attention to fundamentals. Others put more weight on technical charts. Another way of looking at it is to think of...

Shares Up Following Orphan Drug Designation

Classification as an orphan drug incentivizes and supports the development of certain treatments, increasing access to therapies for rare diseases...

NurExone Biologic Receives FDA Orphan-Drug Designation, Accelerating Development of ExoPTEN therapy for Acute Spinal Cord Injury Treatment

TORONTO and HAIFA, Israel, Oct. 30, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Nurexone Biologic Inc (NRX)

Professional-Grade Tools, for Individual Investors.

NRX News

FeaturedSouthern Silver Files NI43-101 Technical Report for its Updated Preliminary Economic Assessment for the Cerro Las Minitas Project

NurExone establishing State-of-the-Art Research and Development Facility in Haifa, Israel

NurExone Presenting Novel Regulatory Pathways for Exosomes Therapies at Global Summit

NurExone’s Intellectual Property Portfolio Expands

NurExone Launches Licensing Efforts for ExoTherapy Platform

Nurexone Biologic Initiates European Orphan Drug Designation Process Following U.S. Grant

NurExone and Inteligex Kick Off Chronic Spinal Cord Injury Research for Multi-Billion Dollar Healthcare Market

NurExone Announces Closing of a Private Placement for Gross Proceeds of Approximately CAD$2 Million

NurExone Biologic Extends Spinal Cord Injury Therapy Portfolio With New RNA Sequences Promoting Healing and Regeneration

NurExone Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Take Part in the Next Generation of Spinal Cord Injury Treatments with These Companies

Orphan Drugs Worth $64 Billion by 2028 and This Micro Cap Could Have One by That Time

When Technicals and Fundamentals Converge, A Nice Uptrend Ensues

Shares Up Following Orphan Drug Designation

NurExone Biologic Receives FDA Orphan-Drug Designation, Accelerating Development of ExoPTEN therapy for Acute Spinal Cord Injury Treatment

NRX Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Nurexone Biologic Inc (NRX) News

Nurexone Biologic Inc (NRX)

Professional-Grade Tools, for Individual Investors.

NRX News

FeaturedSouthern Silver Files NI43-101 Technical Report for its Updated Preliminary Economic Assessment for the Cerro Las Minitas Project

NurExone establishing State-of-the-Art Research and Development Facility in Haifa, Israel

NurExone Presenting Novel Regulatory Pathways for Exosomes Therapies at Global Summit

NurExone’s Intellectual Property Portfolio Expands

NurExone Launches Licensing Efforts for ExoTherapy Platform

Nurexone Biologic Initiates European Orphan Drug Designation Process Following U.S. Grant

NurExone and Inteligex Kick Off Chronic Spinal Cord Injury Research for Multi-Billion Dollar Healthcare Market

NurExone Announces Closing of a Private Placement for Gross Proceeds of Approximately CAD$2 Million

NurExone Biologic Extends Spinal Cord Injury Therapy Portfolio With New RNA Sequences Promoting Healing and Regeneration

NurExone Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Take Part in the Next Generation of Spinal Cord Injury Treatments with These Companies

Orphan Drugs Worth $64 Billion by 2028 and This Micro Cap Could Have One by That Time

When Technicals and Fundamentals Converge, A Nice Uptrend Ensues

Shares Up Following Orphan Drug Designation

NurExone Biologic Receives FDA Orphan-Drug Designation, Accelerating Development of ExoPTEN therapy for Acute Spinal Cord Injury Treatment

NRX Discussion

Your Recent History